Triarylpyrazoles with basic side chains: Development of pyrazole-based estrogen receptor antagonists

Shaun R. Stauffer, Ying R. Huang, Zachary D. Aron, Christopher J. Coletta, Jun Sun, Benita S. Katzenellenbogen, John A. Katzenellenbogen

Research output: Contribution to journalArticlepeer-review

Abstract

Recently, we developed a novel triaryl-substituted pyrazole ligand system that has high affinity for the estrogen receptor (ER) (Fink, B. E.; Mortenson, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Chem. Biol. 1999, 6, 205). Subsequent work has shown that some analogues in this series are very selective for the ERα subtype in terms of binding affinity and agonist potency (Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Sun, J.; Katzenellenbogen, J. A. J. Med. Chem. 2000, submitted). We now investigate how this pyrazole ER agonist system might be converted into an antagonist or a selective estrogen receptor modifier (SERM) by incorporating a basic or polar side chain like those typically found in antiestrogens and known to be essential determinants of their mixed agonist/antagonist character. We selected an N-piperidinyl-ethyl chain as a first attempt, and introduced it at the four possible sites of substitution on the pyrazole core structure to determine the orientation that the pyrazole might adopt in the ER ligand binding pocket. Of these four, the C(5) piperidinyl-ethoxy-substituted pyrazole 5 had by far the highest affinity. Also, it bound to the ER subtype alpha (ERα) with 20-fold higher affinity than to ERβ. In cell-based transcription assays, pyrazole 5 was an antagonist on both ERα and ERβ, and it was also more potent on ERα. Based on structure-binding affinity relationships and on molecular modeling studies of these pyrazoles in a crystal structure of the ERα-raloxifene complex, we propose that pyrazoles having a basic substituent on the C(5) phenyl group adopt a binding mode that is different from that of the pyrazole agonists that lack this group. The most favorable orientation appears to be one which places the N(1) phenol in the A-ring binding pocket so that the basic side chain can adopt an orientation similar to that of the basic side chain of raloxifene.

Original languageEnglish (US)
Pages (from-to)151-161
Number of pages11
JournalBioorganic and Medicinal Chemistry
Volume9
Issue number1
DOIs
StatePublished - Jan 8 2001

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Triarylpyrazoles with basic side chains: Development of pyrazole-based estrogen receptor antagonists'. Together they form a unique fingerprint.

Cite this